SOHO 2026 | Treating peripheral T-cell lymphoma with chemotherapy, avelumab and brentuximab vedotin
Maher Salamoon
• 9 Sep 2026
Maher Salamoon, MD, Al-Baironi Hospital, Damascus, Syria, discusses treating peripheral T-cell lymphoma with a combination of dose-dense, dose-intense chemotherapy, avelumab, and brentuximab vedotin, highlighting promising results after two years of follow-up. Dr Salamoon notes that this combination may be a treatment option for peripheral T-cell lymphoma, a disease with limited treatment guidelines and often disappointing results with traditional therapies. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
